132 related articles for article (PubMed ID: 29508995)
1. Characterization of a 5-HT
Price KL; Lummis SCR
ACS Chem Neurosci; 2018 Jun; 9(6):1409-1415. PubMed ID: 29508995
[TBL] [Abstract][Full Text] [Related]
2. A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Sep; 170(2):391-402. PubMed ID: 23822584
[TBL] [Abstract][Full Text] [Related]
3. Conformational Changes in the 5-HT
Munro L; Ladefoged LK; Padmanathan V; Andersen S; Schiøtt B; Kristensen AS
Mol Pharmacol; 2019 Dec; 96(6):720-734. PubMed ID: 31582575
[TBL] [Abstract][Full Text] [Related]
4. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
Gasiorek A; Trattnig SM; Ahring PK; Kristiansen U; Frølund B; Frederiksen K; Jensen AA
Biochem Pharmacol; 2016 Jun; 110-111():92-108. PubMed ID: 27086281
[TBL] [Abstract][Full Text] [Related]
5. Activation of human 5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site.
Lansdell SJ; Sathyaprakash C; Doward A; Millar NS
Mol Pharmacol; 2015 Jan; 87(1):87-95. PubMed ID: 25338672
[TBL] [Abstract][Full Text] [Related]
6. SR 57227A is a partial agonist/partial antagonist of 5-HT
Nakamura Y; Kondo M; Koyama Y; Shimada S
Biochem Biophys Res Commun; 2019 Jan; 508(2):590-596. PubMed ID: 30509492
[TBL] [Abstract][Full Text] [Related]
7. Subtle Differences among 5-HT
Price KL; Hirayama Y; Lummis SCR
ACS Chem Neurosci; 2017 May; 8(5):1085-1091. PubMed ID: 28367632
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.
Trattnig SM; Harpsøe K; Thygesen SB; Rahr LM; Ahring PK; Balle T; Jensen AA
J Biol Chem; 2012 Jul; 287(30):25241-54. PubMed ID: 22589534
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the
Brams M; Govaerts C; Kambara K; Price KL; Spurny R; Gharpure A; Pardon E; Evans GL; Bertrand D; Lummis SC; Hibbs RE; Steyaert J; Ulens C
Elife; 2020 Jan; 9():. PubMed ID: 31990273
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT
Powell AD; Grafton G; Roberts A; Larkin S; O'Neill N; Palandri J; Otvos R; Cooper AJ; Ulens C; Barnes NM
Br J Pharmacol; 2016 Dec; 173(24):3467-3479. PubMed ID: 27677804
[TBL] [Abstract][Full Text] [Related]
11. Direct interaction of the resistance to inhibitors of cholinesterase type 3 protein with the serotonin receptor type 3A intracellular domain.
Nishtala SN; Mnatsakanyan N; Pandhare A; Leung C; Jansen M
J Neurochem; 2016 May; 137(4):528-38. PubMed ID: 26875553
[TBL] [Abstract][Full Text] [Related]
12. Proline Residues in the Transmembrane/Extracellular Domain Interface Loops Have Different Behaviors in 5-HT
Mosesso R; Dougherty DA; Lummis SCR
ACS Chem Neurosci; 2019 Jul; 10(7):3327-3333. PubMed ID: 31273982
[TBL] [Abstract][Full Text] [Related]
13. Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT
Ladefoged LK; Munro L; Pedersen AJ; Lummis SCR; Bang-Andersen B; Balle T; Schiøtt B; Kristensen AS
Mol Pharmacol; 2018 Dec; 94(6):1421-1434. PubMed ID: 30257860
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of two prokaryotic pentameric ligand-gated ion channel chimeras - role of the GLIC transmembrane domain in proton sensing.
Hénault CM; Baenziger JE
Biochim Biophys Acta Biomembr; 2017 Feb; 1859(2):218-227. PubMed ID: 27845033
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.
Kurzwelly D; Barann M; Kostanian A; Combrink S; Bönisch H; Göthert M; Brüss M
Pharmacogenetics; 2004 Mar; 14(3):165-72. PubMed ID: 15167704
[TBL] [Abstract][Full Text] [Related]
16. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
[TBL] [Abstract][Full Text] [Related]
17. Common Anesthetic-binding Site for Inhibition of Pentameric Ligand-gated Ion Channels.
Kinde MN; Bu W; Chen Q; Xu Y; Eckenhoff RG; Tang P
Anesthesiology; 2016 Mar; 124(3):664-73. PubMed ID: 26756520
[TBL] [Abstract][Full Text] [Related]
18. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
[TBL] [Abstract][Full Text] [Related]
19. Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.
Lochner M; Lummis SC
Biophys J; 2010 Apr; 98(8):1494-502. PubMed ID: 20409468
[TBL] [Abstract][Full Text] [Related]
20. 5-HT3 receptor ion size selectivity is a property of the transmembrane channel, not the cytoplasmic vestibule portals.
McKinnon NK; Reeves DC; Akabas MH
J Gen Physiol; 2011 Oct; 138(4):453-66. PubMed ID: 21948949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
